Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aurinia Pharmaceuticals Inc.

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Announces 2023 Annual General Meeting Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.